From my colleague Drew Joseph: Just a few months after its unveiling, the startup Ottimo Pharma said Thursday it had raised a $140 million Series A round, a hefty sum that reflects the biopharma’s industry excitement around the targets Ottimo’s going after with its experimental cancer therapy. The financing was led by OrbiMed, Avoro Capital, and Samsara BioCapital,...